Madrigal finally de-livers
20 December 2022
Madrigal just released long-awaited positive data for a deadly liver disease with no cure: NASH. The share price is up >200%, with both patients and investors welcoming the news. One of our most awaited catalysts of 2022 really kept us waiting until the end, and it was worth it.
Bottom line
NASH, which stands for Non-Alcoholic SteatoHepatitis, is a condition in which excess fat is stored inside liver cells, making it harder for the liver to function until it stops working altogether. The prevalence of this terrible liver disease is 6% globally and rising. Combined with no therapeutic solution, this figure alone should send shivers down anyone's spine. The market for any good drug for that indication is north of $25bn.
Madrigal Pharmaceuticals, a prominent player in the space, teased patients and investors all year round, announcing a data release for 4Q22 for one of the most awaited catalysts. With less than ten business days left, they released excellent data. This piece of news was well received by all, opening a venue for accelerated approval in 2023 and hope for millions of patients.
This article is available to logged users.
Sign in or request a login.
Disclaimer
This report has been produced by the organizational unit responsible for investment research (Research unit) of atonra Partners and sent to you by the company sales representatives.
As an internationally active company, atonra Partners SA may be subject to a number of provisions in drawing up and distributing its investment research documents. These regulations include the Directives on the Independence of Financial Research issued by the Swiss Bankers Association. Although atonra Partners SA believes that the information provided in this document is based on reliable sources, it cannot assume responsibility for the quality, correctness, timeliness or completeness of the information contained in this report.
The information contained in these publications is exclusively intended for a client base consisting of professionals or qualified investors. It is sent to you by way of information and cannot be divulged to a third party without the prior consent of atonra Partners. While all reasonable effort has been made to ensure that the information contained is not untrue or misleading at the time of publication, no representation is made as to its accuracy or completeness and it should not be relied upon as such.
Past performance is not indicative or a guarantee of future results. Investment losses may occur, and investors could lose some or all of their investment. Any indices cited herein are provided only as examples of general market performance and no index is directly comparable to the past or future performance of the Certificate.
It should not be assumed that the Certificate will invest in any specific securities that comprise any index, nor should it be understood to mean that there is a correlation between the Certificate’s returns and any index returns.
Any material provided to you is intended only for discussion purposes and is not intended as an offer or solicitation with respect to the purchase or sale of any security and should not be relied upon by you in evaluating the merits of investing inany securities.
Back to research
